BU Faculty Spin-off Company ExProDx Receives OTD Launch Award
ExProDx, Inc., a molecular diagnostics company founded by BU School of Medicine professors Avrum Spira, MD and Jerome Brody, MD, has received a $175,000 Launch Award from the Office of Technology Development (OTD). ExProDx is developing DNA-based diagnostic tests to determine a person’s risk of developing lung cancer and tests that diagnose lung cancer at a very early stage when it is most treatable. The founders have published several studies in peer-reviewed journals on their research, the most resent of which was published in the prestigious journal Nature Medicine this month. Lung cancer is the second most common cancer in the world and one of the most lethal, resulting in over one million deaths/year. With early diagnosis many patients suffering from lung cancer can be cured. The company is using the proceeds from the Launch Award to prepare for an upcoming clinical trial, legal and regulatory consultants, personnel, and working capital. The company seeks to raise additional capital over the next 12 months to begin a major multi-site technology validation study. Data from this study will be used to seek FDA approval and clear the way for clinical use of ExProDx’s product in the marketplace.
An article on ExProDx and its founders appeared in May 25-31 issues of Mass High Tech (click Mass High Tech for story).